Answers are grounded in this paper and cite their sources.
Various models have been proposed to set requirements for imprecision in clinical laboratory sciences. The idea of establishing a hierarchy for these models based on their objectivity has been proposed recently (1)(2). Briefly, in the different models, hierarchically ordered, the requirement for imprecision is based on: the effect of imprecision on clinical outcomes in specific clinical situations; within-subject biological variation; clinicians’ opinions; experts’ recommendations; interlaboratory comparisons organizers; and current state of the art. Models higher up in the hierarchy are to be preferred to those at lower levels, but the hierarchy may change depending on the specific clinical purpose of the measured quantity (e.g., screening, diagnostics, or monitoring) (1)(2). Notwithstanding this, we think there is evidence enough to demonstrate that the use of the current state-of-the-art model should be the second preferred model, replacing the use of within-subject biological variation for setting requirements for imprecision for clinical laboratories. Let CVM be the measurement procedure imprecision (metrological coefficient of variation) and CVBw be the coefficient of variation corresponding to within-subject biological variation. At the moment, the model for setting the allowable imprecision based on within-subject biological variation outlines three situations (1): Desirable performance: CVM < 0.50 CVBw. Useful when the allowable imprecision value generated following this inequality is viewed as being generally applicable. Minimum performance: CVM < 0.75 CVBw. Useful for measurement procedures for which the desirable performance (CVM < 0.50 CVBw) is not attainable with current technology and methodology. Optimum performance: CVM < 0.25 CVBw. Useful for measurement procedures for which the desirable performance (CVM < 0.50 CVBw) is easily achieved with current technology and methodology. From this equation, when CVM = 0.25 CVBw, then CVM is 24.2% of CVT; when CVM = 0.50 CVBw, then CVM is 44.7% of CVT; and when CVM = 0.75 CVBw, then CVM is 60.0% of CVT. Obviously, the selection of these three factors instead of any others is not objective and independent of external situations, but is based on the feasibility of the allowable imprecision value obtained, that is to say, it is really based on the state of the art! The use of this model has additional weakness: (a) there is great variation among CVBw values (Table 1 ); and (b) in some cases the within-subject biological variation is so small that requirements based on such data may not be achieved with the routine systems of measurement. The conclusion from all of the above may be that setting requirements for imprecision from within-subject biological variation data is as arbitrary as setting these requirements from a fractile of participating laboratories in external quality assessment schemes (daily interlaboratory quality-control programs), that is to say, from the state of the art. One of the three situations proposed in the model using within-subject biological variation is the so-called “optimum performance”. Because optimum is the superlative of good, “optimum performance” means “the best performance”; can we really accept that when CVM = 0.25 CVBw is the best performance regarding imprecision? In 1980, Ralph Gräsbeck wrote “[… ] An authoritative Scandinavian meeting stated this in the following terms: ‘The analytical precision must be so good that it is possible to decide whether a normal intraindividual variation or a pathological deviation is present’. To this we should today perhaps add: ‘[…] and that also hitherto undescribed physiological variations are detectable in the individual’ ” (3). Keeping in mind this idea, with which we agree absolutely, imprecision should ideally be zero; in other words, the optimum imprecision is really zero. Consequently, any requirement for imprecision should be consistent with such an optimum value. Generally, the degree of metrological quality that a clinical laboratory can achieve is limited by its measurement systems, which for financial reasons should be working throughout their lifespans (amortization); thus, the requirement for imprecision should be possible to achieve and updateable. Such requirements can be one of the fractiles of the distribution of imprecisions from all participating laboratories in different external quality assessment schemes, provided that in these schemes imprecision is estimated from all of the results corresponding to a particular control material. This control material should be measured in each laboratory every day that a run is performed (4)(5). Every country or region can decide which is the most appropriate fractile for each quantity. Because science and technology are constantly advancing, the requirements based in the state of the art should be periodically updated (perhaps every 5 years), and consequently, the overall trend in requirements will be toward zero. This fact is consistent with the goal stated above: imprecision should ideally be zero. With this model, depending on quantities and external quality assessment schemes, requirements may be established for one, two, or three values of the quantity. The use of state of the art as a given fractile of imprecision has the strategic advantage for regulation purposes that we can know directly in advance the approximate fraction of laboratories in a given region that will achieve the requirements. The only weakness of this proposal is that it depends on publication of the fractiles of imprecision by the organizers of external quality assessment programs (generalization of this activity should be encouraged). In spite of all of the above, when a measurement system for a “new” biological quantity is developed by the in vitro diagnostics industry, the requirements for imprecision based on biological variation should always be taken into account as a guide because, as a general rule, the smaller the within-subject biological variation, the smaller the imprecision must be. However, industry, for reasons of competition and independently of clinical chemists’ wishes and theories, will be motivated to develop measurement systems in which imprecision will be progressively closer to zero. Examples of the range of the observed means or medians of within-subject coefficients of variation (CVBw) observed in different studies with a time span greater than 1 month, and on the range of CVBw observed in 20 healthy individuals in one study. According to IUPAC and IFCC (8): S, serum; cat.c., catalytic concentration; subst.c, amount of substance concentration; mass c., mass concentration. n, number of studies. Examples of the range of the observed means or medians of within-subject coefficients of variation (CVBw) observed in different studies with a time span greater than 1 month, and on the range of CVBw observed in 20 healthy individuals in one study. According to IUPAC and IFCC (8): S, serum; cat.c., catalytic concentration; subst.c, amount of substance concentration; mass c., mass concentration. n, number of studies.
No takes yet. Share an insight, caveat, or question.
Fuentes‐Arderiu et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: